Table 2.
Characteristics of the 13 patients with liver biopsy after OLT
| At transplantation | At biopsy | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt | Age (years) | Gender | HCC | HBeAg | HBcrAg (log10 IU/mL) | Serum HBV-DNA (log10 copies/mL) | Intrahepatic cccDNA (log10 copies/cell) | Follow-up (days) | HBeAg | HBcrAg (log10 IU/mL) | Serum HBV-DNA (log10 copies/mL) | cccDNA (log10 copies/cell) | Immunosuppressants | Prophylaxis | ||||
| Steroid | CyA | FK | MMF | Antiviral agents | Duration (days) | |||||||||||||
| 35 | 26 | M | Y | + | NoA | 4.5 | NoA | 2,221 | − | UD | UD | −1.12 | N | N | Y | Y | LAM | 2,269 |
| 115 | 50 | M | Y | − | UD | UD | −1.25 | 895 | NoA | 3.2 | UD | UD | N | N | Y | Y | LAM | 943 |
| 97 | 50 | M | Y | + | 5.7 | 3.9 | NoA | 1,283 | − | 3.2 | UD | −0.46 | N | Y | N | N | LAM + ADV | 1,787 |
| 120 | 57 | M | Y | − | 5.2 | 2.7 | −1.20 | 1,082 | NoA | UD | NoA | −3.19 | N | Y | Y | Y | LAM | 1,135 |
| 129 | 48 | M | N | + | 3.8 | 4.8 | NoA | 709 | NoA | 3.8 | NoA | UD | N | N | Y | Y | LAM | 720 |
| 148 | 56 | F | Y | + | 3.7 | 2.7 | −0.24 | 370 | − | UD | UD | UD | Y | N | Y | N | LAM | 690 |
| 148 | 56 | F | Y | + | 3.7 | 2.7 | −0.24 | 553 | NoA | UD | NoA | UD | Y | N | Y | N | LAM | 873 |
| 177 | 37 | M | Y | − | 3.9 | UD | NoA | 485 | − | 3.0 | UD | UD | N | N | Y | Y | LAM + ADV | 2,057 |
| 167 | 63 | M | N | − | 4.1 | UD | −0.33 | 485 | − | UD | UD | −2.23 | Y | N | Y | Y | LAM + ADV | 2,278 |
| 181 | 52 | M | N | − | 5.1 | UD | −1.81 | 338 | − | 3.4 | UD | −2.50 | Y | N | Y | N | ETV | 1,301 |
| 153 | 47 | F | N | + | 3.4 | 5.8 | NoA | 401 | NoA | 3.1 | UD | −0.70 | Y | N | Y | Y | LAM | 415 |
| 135 | 48 | M | Y | + | 5.8 | 3.5 | 0.28 | 632 | − | 3.4 | UD | −1.38 | N | N | Y | Y | LAM | 735 |
| 159 | 54 | M | Y | − | 3.2 | UD | −1.61 | 385 | NoA | UD | NoA | UD | Y | N | Y | Y | ETV | 390 |
| 94 | 53 | M | Y | − | 55 | 42 | 0.32 | 1,409 | − | 33 | UD | −2.01 | N | Y | N | Y | LAM + ADV | 2,179 |
ADV adefovir, cccDNA covalently closed circular deoxyribonucleic acid, CyA cyclosporine A, ETV entecavir, F female, FK tacrolimus, HBcrAg hepatitis B core-related antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, HCC hepatocellular carcinoma, LAM lamivudine, M male, MMF mycophenolate mofetil, N no, NA not assessed, OLT orthotopic liver transplantation, Pt patient number, UD undetectable, Y yes